8,381 results on '"SITAGLIPTIN"'
Search Results
2. In Vitro and in Silico Analysis of α -Amylase Inhibitory Activity of Ethanolic Extract of Adhatoda vasica Leaves.
- Author
-
Yadav, Chandrajeet K., KC, Sandhya, and Thapa, Shankar
- Subjects
IN vitro studies ,COMPUTER-assisted molecular modeling ,ETHANOL ,SITAGLIPTIN ,HYPOGLYCEMIC agents ,PHYTOCHEMICALS ,ENZYMES ,DESCRIPTIVE statistics ,PLANT extracts ,QUERCETIN ,BLOOD sugar ,MOLECULAR structure ,LEAVES ,DATA analysis software ,AMYLASES ,DIABETES ,ACARBOSE ,SPECTROPHOTOMETRY - Abstract
Objective: Diabetic individuals have a higher probability of suffering from illness and death due to small blood vessel-related problems such as retinopathy, neuropathy, nephropathy, and stroke than other complications. There are many synthetic anti-diabetic agents available, but these can be expensive and have undesirable pathological effects. The enzyme α-amylase (hydrolase), catalyzes the hydrolysis of starch to maltose and glucose via the cleavage of α-1,4-glucosidic linkages. Diabetes mellitus patients may benefit from a therapeutic strategy that involves slowing the hydrolysis of starch by inhibiting the activity of α-amylase. Thus, looking for cost-effective, natural, and safe antidiabetic agents is essential. This study aims to screen phytoconstituents and evaluate the in-vitro and in-silico α-amylase inhibitory activity of the ethanolic extract of Adhatoda vasica leaves. Methods: The extraction of Adhatoda vasica leaves was performed using ethanol via the Soxhlet extraction process. Different concentrations (100 μg/mL to 1000 μg/mL) of ethanolic extract, Acarbose, and Sitagliptin, were prepared and evaluated for α-amylase inhibitory activity using the spectrophotometric method. Molecular docking (AutodockVina 1.2.0) and toxicity profiling (SToPToX web server) studies were performed. Results: The ethanolic extract of Adhatoda vasica leaves showed the highest percentage inhibition against α-amylase (56.763 ± 0.0035) at a concentration of 1000 μg/mL. The in-silico study supported this inhibitory activity. Vasicoline (C5) and Quercetin (C9), the active constitute of Adhatoda vasica, showed the best binding energies of −8.3 and −8.0 Kcal/mol, respectively against α-amylase enzyme (PDBID: 4W93). A toxicity study revealed the safety profile of the plant extract. Conclusion: It was concluded that Adhatoda vasica leaves possess some bioactive compounds that are responsible for controlling blood glucose levels, and their identification, purification, and isolation may lead to the development of new therapeutic agents with fewer side effects than the available drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study.
- Author
-
Sugiyama, Takehiro, Furuno, Takashi, Ichinose, Yuichi, Iwagami, Masao, Ihana‐Sugiyama, Noriko, Imai, Kenjiro, Kakuwa, Tamaki, Rikitake, Ryoko, Ohsugi, Mitsuru, Higashi, Takahiro, Iso, Hiroyasu, and Ueki, Kohjiro
- Subjects
- *
PROPORTIONAL hazards models , *NATIONAL health insurance , *SITAGLIPTIN , *DISEASE risk factors , *CONFIDENCE intervals - Abstract
ABSTRACT Aims/Introduction Materials and Methods Results Conclusions A recent US Food and Drug Administration report highlighted concerns over nitrosamine (7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine [NTTP]) impurities in sitagliptin, prompting investigations into its safety profile. The present study aimed to determine if the use of NTTP‐contaminated sitagliptin, in comparison with other dipeptidyl peptidase‐4 (DPP‐4) inhibitors, is associated with an increased cancer risk.This retrospective cohort study secondarily used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, encompassing data on >120 million individuals. The study involved patients who initiated DPP‐4 inhibitor therapy (sitagliptin or other DPP‐4 inhibitors) and continued its exclusive use for 3 years. Sitagliptin users were compared with other DPP‐4 inhibitor users for assessing the occurrence of cancers, as defined by diagnosis codes. Further analyses focused on specific types of cancer, using either diagnosis codes or a combination of diagnosis and procedure codes. We also carried out various sensitivity analyses, including those with different exposure periods.Sitagliptin users (149,120 patients, 388,356 person‐years) experienced 9,643 cancer incidences (2,483.0/100,000 person‐years) versus 12,621 incidences (2,504.4/100,000 person‐years) among other DPP‐4 inhibitor users (199,860 patients, 503,952 person‐years), yielding a minimal difference (incidence rate ratio 0.99, 95% confidence interval 0.97–1.02). A multiple Cox proportional hazards model showed no significant association between sitagliptin use and overall cancer incidence (hazard ratio 1.01, 95% confidence interval 0.98–1.04). Findings were also consistent across cancer types and sensitivity analyses.We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP‐contaminated sitagliptin, although continued investigation is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Sitagliptin synergizes 5‐fluorouracil efficacy in colon cancer cells through MDR1‐mediated flux impairment and down regulation of NFκB2 and p‐AKT survival proteins.
- Author
-
Eisa, Asmaa, Hanafy, Shaden M., Khalil, Hany, and Elshal, Mohamed F.
- Subjects
COLON cancer ,THYMIDYLATE synthase ,CANCER cells ,MOLECULAR docking ,SITAGLIPTIN - Abstract
5‐fluorouracil (5‐FU) is an inexpensive treatment for colon cancer; however, its efficacy is limited by chemoresistance. This study investigates the combination therapy approach of 5‐FU with Sitagliptin (Sita), a diabetic drug with potential cancer‐modulating effects. The combination was evaluated in vitro and in silico, focusing on the effects of Sita and 5‐FU on colon cancer cells. The results showed that the addition of Sita significantly decreased the IC50 of 5‐FU compared to 5‐Fu monotherapy. The study also found that Sita and 5‐FU interact synergistically, with a combination index below 1. Sita successfully lowered the 5‐FU dosage reduction index, decreasing the expression of MDR1 mRNA and p‐AKT and NFκB2 subunits p100/p52 protein. Molecular docking analyses confirmed Sita's antagonistic action on MDR1 and thymidylate synthase proteins. The study concludes that sitagliptin can target MDR1, increase apoptosis, and significantly reduce the expression of p‐AKT and NFκB2 cell‐survival proteins. These effects sensitize colon cancer cells to 5‐FU. Repurposing sitagliptin may enhance the anticancer effects of 5‐FU at lower dosages. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Adverse cardiac events of hypercholesterolemia are enhanced by sitagliptin in sprague dawley rats.
- Author
-
Palfrey, Henry A., Kumar, Avinash, Pathak, Rashmi, Stone, Kirsten P., Gettys, Thomas W., and Murthy, Subramanyam N.
- Subjects
- *
HYPERCHOLESTEREMIA prevention , *TISSUE arrays , *RESEARCH funding , *MAJOR adverse cardiovascular events , *SITAGLIPTIN , *CARDIOTONIC agents , *CARDIOVASCULAR diseases risk factors , *METHIONINE , *OXIDATIVE stress , *RATS , *ANIMAL experimentation , *COLLAGEN , *DIET therapy for heart diseases , *DIABETES , *PHARMACODYNAMICS - Abstract
Background: Cardiovascular disease (CVD) affects millions worldwide and is the leading cause of death among non-communicable diseases. Western diets typically comprise of meat and dairy products, both of which are rich in cholesterol (Cho) and methionine (Met), two well-known compounds with atherogenic capabilities. Despite their individual effects, literature on a dietary combination of the two in the context of CVD are limited. Therefore, studies on the combined effects of Cho and Met were carried out using male Sprague Dawley rats. An additional interest was to investigate the cardioprotective potential of sitagliptin, an anti-type 2 diabetic drug. We hypothesized that feeding a dietary combination of Cho and Met would result in adverse cardiac effects and would be attenuated upon administration of sitagliptin. Methods: Adult male Sprague-Dawley rats were fed either a control (Con), high Met (1.5%), high Cho (2.0%), or high Met (1.5%) + high Cho (2.0%) diet for 35 days. They were orally gavaged with an aqueous preparation of sitagliptin (100 mg/kg/d) or vehicle (water) from day 10 through 35. On day 36, rats were euthanized, and tissues were collected for analysis. Results: Histopathological evaluation revealed a reduction in myocardial striations and increased collagen deposition in hypercholesterolemia (HChol), responses that became exacerbated upon sitagliptin administration. Cardiac pro-inflammatory and pro-fibrotic responses were adversely impacted in similar fashion. The addition of Met to Cho (MC) attenuated all adverse structural and biochemical responses, with or without sitagliptin. Conclusions: Adverse cardiac outcomes in HChol were enhanced by the administration of sitagliptin, and such effects were alleviated by Met. Our findings could be significant for understanding or revisiting the risk-benefit evaluation of sitagliptin in type 2 diabetics, and especially those who are known to consume atherogenic diets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia.
- Author
-
Harris, Dwight D., Sabe, Sharif A., Broadwin, Mark, Stone, Chris, Bellam, Krishna, Malhotra, Akshay, Abid, M. Ruhul, and Sellke, Frank W.
- Subjects
- *
CD26 antigen , *MYOCARDIAL ischemia , *YORKSHIRE swine , *SITAGLIPTIN , *SWINE , *INSULIN receptors , *SWINE breeds - Abstract
Objective: Although both clinical data and animal models suggest cardiovascular benefits following administration of Dipeptidyl Peptidase 4 (DPP-4) inhibitors, the underlying mechanisms remain unclear. We therefore sought to evaluate the effect of the DPP-4 inhibitor sitagliptin on myocardial fibrosis, and insulin signaling in chronic myocardial ischemia using a swine model. An ameroid constrictor placement on the left coronary circumflex artery of thirteen Yorkshire swine to model chronic myocardial ischemia. After two weeks of recovery, swine were assigned to one of two groups: control (CON, n = 8), or sitagliptin 100mg daily (SIT, n = 5). After 5 weeks of treatment, the swine underwent terminal harvest with collection of myocardial tissue. Fibrosis was quantified using Masson's trichrome. Protein expression was quantified by Immunoblotting. Trichrome stain demonstrated a significant decrease in perivascular and interstitial fibrosis in the SIT group relative to CON (all p<0.05). Immunoblot showed a reduction in Jak2, the pSTAT3 to STAT 3 Ratio, pSMAD 2/3, and SMAD 2/3, and an increase in STAT 3 in the SIT group relative to CON (all p<0.05). SIT treatment was associated with increased expression of insulin receptor one and decreased expression of makers for insulin resistance, including phospho-PKC- alpha, RBP-4, SIRT1, and PI3K (p<0.05). Sitagliptin results in a reduction in perivascular and interstitial fibrosis and increased insulin sensitivity in chronically ischemic swine myocardium. This likely contributes to the improved cardiovascular outcomes seen with DPP-4 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. De-indexed estimated glomerular filtration rates for the dosing of oral antidiabetic drugs in patients with chronic kidney disease.
- Author
-
Pluquet, Maxime, Metzger, Marie, Jacquelinet, Christian, Combe, Christian, Fouque, Denis, Laville, Maurice, Frimat, Luc, Massy, Ziad A., Liabeuf, Sophie, and Laville, Solène M.
- Subjects
CHRONIC kidney failure ,GLOMERULAR filtration rate ,ORAL medication ,CHRONICALLY ill ,INAPPROPRIATE prescribing (Medicine) ,METFORMIN ,SITAGLIPTIN ,INFANT formulas - Abstract
Introduction: Adjusting drug dose levels based on equations that standardize the estimated glomerular filtration rate (eGFR) to a body surface area (BSA) of 1.73m2 can pose challenges, especially for patients with extremely high or low body mass index (BMI). The objective of the present study of patients with CKD and diabetes was to assess the impact of deindexing creatinine-based equations on estimates of kidney function and on the frequency of inappropriate prescriptions of oral antidiabetic drugs (OADs). Methods: The prospective CKD-REIN cohort is comprised of patients with eGFR <60 mL/min/1.73m². The inclusion criteria for this study were the use of OADs and the availability of data on weight, height and serum creatinine. We compared data for three BMI subgroups (group 1 <30 kg/m²; group 2 30-34.9 kg/m²; group 3 =35 kg/m²). Inappropriate prescriptions (contraindicated or over-dosed drugs) were assessed with regard to the summary of product characteristics and the patient's kidney function estimated with the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the 2021 CKD-EPI equation, the Modification of Diet in Renal Disease (MDRD) equation, the European Kidney Function Consortium (EKFC) equation, their deindexed estimates, and the Cockcroft-Gault (CG) formula. The impact of deindexing the equations was evaluated by assessing 1) the difference between the indexed and deindexed eGFRs, and 2) the difference in the proportion of patients with at least one inappropriate OAD prescription between the indexed and deindexed estimates. Results: At baseline, 694 patients were receiving OADs. The median BMI was 30.7 kg/m², the mean BSA was 1.98m², and 90% of patients had a BSA >1.73m². Deindexing the kidney function estimates led to higher eGFRs, especially in BMI group 3. The proportion of patients with at least one inappropriate prescription differed greatly when comparing indexed and deindexed estimates. The magnitude of the difference increased with the BMI: when comparing BMI group 1 with BMI group 3, the difference was respectively -4% and -10% between deindexed 2021 CKD-EPI and indexed CKD-EPI. Metformin and sitagliptin were the most frequent inappropriately prescribed OADs. Conclusion: We highlight significant differences between the BSA-indexed and deindexed versions of equations used to estimate kidney function, emphasizing the importance of using deindexed estimates to adjust drug dose levels - especially in patients with an extreme BMI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study.
- Author
-
Lee, Yang-Ming, Lin, Pei Ru, and Sia, Hon-Ke
- Subjects
- *
GLYCEMIC control , *TYPE 2 diabetes , *PEOPLE with diabetes , *HYPOGLYCEMIC agents , *GLYCOSYLATED hemoglobin , *SITAGLIPTIN , *PROPENSITY score matching - Abstract
Our study aims to compare the efficacy of oral antidiabetic therapy to early insulinization on glycemic control among newly diagnosed type 2 diabetes patients in real-world clinical practice. A retrospective cohort study conducted at a medical center in Taiwan analyzed 1256 eligible patients from January 2007 to December 2017. Propensity score matching resulted in well-balanced groups of 94 patients each in the oral antidiabetic drug (OAD) and early insulinization cohorts. Glycemic outcomes were assessed in both groups. Patients exclusively using OAD showed consistently lower glycated hemoglobin (HbA1c) levels at 3, 12, 24, and 36 months compared to insulin users. At later periods, 77.7% of OAD users achieved glycemic control versus 64.9% of insulin users, with a marginally significant difference. Subgroup analyses suggested a trend favoring well-controlled diabetes in the OAD group, though not statistically significant. Our study finds oral antidiabetic therapy is not inferior to early insulinization for glycemic control in newly diagnosed type 2 diabetes patients, irrespective of initial HbA1c levels. This supports oral therapy as a rational treatment option, even in cases with elevated HbA1c at diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression.
- Author
-
Ro, Du Hyun, Cho, Gun Hee, Kim, Ji Yoon, Min, Seong Ki, Yang, Ha Ru, Park, Hee Jung, Wang, Sun Young, Kim, You Jung, Lee, Myung Chul, Bae, Hyun Cheol, and Han, Hyuk‐Soo
- Subjects
- *
CD26 antigen , *LABORATORY rats , *CELLULAR aging , *OSTEOARTHRITIS , *INTRA-articular injections , *MATRIX metalloproteinases - Abstract
Senescent cells increase in many tissues with age and induce age‐related pathologies, including osteoarthritis (OA). Senescent chondrocytes (SnCs) are found in OA cartilage, and the clearance of those chondrocytes prevents OA progression. However, targeting SnCs is challenging due to the absence of a senescent chondrocyte‐specific marker. Therefore, we used flow cytometry to screen and select senescent chondrocyte surface markers and cross‐validated with published transcriptomic data. Chondrocytes expressing dipeptidyl peptidase‐4 (DPP‐4), the selected senescent chondrocyte‐specific marker, had multiple senescence phenotypes, such as increased senescence‐associated‐galactosidase, p16, p21, and senescence‐associated secretory phenotype expression, and showed OA chondrocyte phenotypes. To examine the effects of DPP‐4 inhibition on DPP‐4+ SnCs, sitagliptin, a DPP‐4 inhibitor, was treated in vitro. As a result, DPP‐4 inhibition selectively eliminates DPP‐4+ SnCs without affecting DPP‐4‐ chondrocytes. To assess in vivo therapeutic efficacy of targeting DPP‐4+ SnCs, three known senolytics (ABT263, 17DMAG, and metformin) and sitagliptin were comparatively verified in a DMM‐induced rat OA model. Sitagliptin treatment specifically and effectively eliminated DPP‐4+ SnCs, compared to the other three senolytics. Furthermore, Intra‐articular sitagliptin injection to the rat OA model increased collagen type II and proteoglycan expression and physical functions and decreased cartilage destruction, subchondral bone plate thickness and MMP13 expression, leading to the amelioration of OA phenotypes. Collectively, OARSI score was lowest in the sitagliptin treatment group. Taken together, we verified DPP‐4 as a surface marker for SnCs and suggested that the selective targeting of DPP‐4+ chondrocytes could be a promising strategy to prevent OA progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Ecofriendly Chromatographic Assay of Metformin Combinations; Content Uniformity Tests and Toxicity Profiling.
- Author
-
Emam, Aml A, Abdelaleem, Eglal A, Magdy, Fatma, Gouda, Ahmed M, and Abdallah, Fatma F
- Subjects
- *
MELAMINE , *TOXICITY testing , *METFORMIN , *SILICA gel , *UNIFORMITY , *ETHYL acetate - Abstract
Accurate, sensitive and green HPTLC chromatographic method was proposed for simultaneous determination of metformin, glipizide and sitagliptin in the presence of metformin potential toxic impurities melamine and cyanoguanidine. The separation was completed on silica gel HPTLC F254 plates using a mixture of ethyl acetate: methanol: ammonia: formic acid (7: 2: 0.2: 0.2, by volume) as a developing system with UV scanning for the developed bands at 235 nm. The R f values for metformin, glipizide, sitagliptin, melamine and cyanoguanidine were 0.17, 0.84, 0.67, 0.47 and 0.75, respectively. Linear responses were observed in the ranges of 0.2–3, 0.07–1.5, 1.5–5, 0.8–4 and 0.4–2 μg/band with correlation coefficients of 0.9999, 0.9998, 0.9997, 0.9996 and 0.9998 for metformin, glipizide, sitagliptin, melamine and cyanoguanidine, respectively. The proposed method was validated as per ICH criteria with respect to linearity, accuracy, precision, specificity and robustness. The validated method was successfully applied for determination of the studied drugs in Janumet® and Engilor® tablets; also, the results were statistically compared to those obtained by the reported spectrophotometric method and no significant difference was found between them. This method permitted the accurate simultaneous determination of the studied drugs, indicating its ability to be used for routine quality control assays of these drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Individual dipeptidyl peptidase‐4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta‐analysis.
- Author
-
Mitsuboshi, Satoru, Morizumi, Makoto, Kotake, Kazumasa, Kaseda, Ryohei, and Narita, Ichiei
- Subjects
- *
CD26 antigen , *ACUTE kidney failure , *TYPE 2 diabetes , *CORONARY artery bypass , *RANDOM effects model , *OUTLIERS (Statistics) - Abstract
This network meta‐analysis of randomized controlled trials aimed to determine whether any individual dipeptidyl peptidase‐4 (DPP‐4) inhibitors increase the risk of acute kidney injury (AKI). The Medical Literature Analysis and Retrieval System Online via PubMed, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were systematically searched to identify relevant studies. The primary outcome was AKI. A frequentist network meta‐analysis was performed using a random‐effects model to account for heterogeneity. Twenty‐nine studies involving 56 117 participants were included. There were 918 cases of AKI (1.63%). The risk of bias was generally considered to be low. The only DPP‐4 inhibitor that significantly increased the frequency of AKI when compared with placebo was sitagliptin (risk ratio 1.65, 95% confidence interval 1.22–2.23). However, because one study showed significant outliers in the funnel plot, in a highly heterogeneous population composed solely of patients undergoing surgery for coronary artery bypass graft, we conducted a post‐hoc sensitivity analysis to exclude this study. The results showed no statistically significant difference in the risk of AKI between sitagliptin and placebo. Individual DPP‐4 inhibitors do not appear to increase the risk of AKI. However, sitagliptin may be associated with AKI in patients with underlying severe cardiovascular disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Adverse cardiac events of hypercholesterolemia are enhanced by sitagliptin in sprague dawley rats
- Author
-
Henry A. Palfrey, Avinash Kumar, Rashmi Pathak, Kirsten P. Stone, Thomas W. Gettys, and Subramanyam N. Murthy
- Subjects
Cholesterol ,Methionine ,Cardiovascular ,Sitagliptin ,Nutrition. Foods and food supply ,TX341-641 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Cardiovascular disease (CVD) affects millions worldwide and is the leading cause of death among non-communicable diseases. Western diets typically comprise of meat and dairy products, both of which are rich in cholesterol (Cho) and methionine (Met), two well-known compounds with atherogenic capabilities. Despite their individual effects, literature on a dietary combination of the two in the context of CVD are limited. Therefore, studies on the combined effects of Cho and Met were carried out using male Sprague Dawley rats. An additional interest was to investigate the cardioprotective potential of sitagliptin, an anti-type 2 diabetic drug. We hypothesized that feeding a dietary combination of Cho and Met would result in adverse cardiac effects and would be attenuated upon administration of sitagliptin. Methods Adult male Sprague-Dawley rats were fed either a control (Con), high Met (1.5%), high Cho (2.0%), or high Met (1.5%) + high Cho (2.0%) diet for 35 days. They were orally gavaged with an aqueous preparation of sitagliptin (100 mg/kg/d) or vehicle (water) from day 10 through 35. On day 36, rats were euthanized, and tissues were collected for analysis. Results Histopathological evaluation revealed a reduction in myocardial striations and increased collagen deposition in hypercholesterolemia (HChol), responses that became exacerbated upon sitagliptin administration. Cardiac pro-inflammatory and pro-fibrotic responses were adversely impacted in similar fashion. The addition of Met to Cho (MC) attenuated all adverse structural and biochemical responses, with or without sitagliptin. Conclusions Adverse cardiac outcomes in HChol were enhanced by the administration of sitagliptin, and such effects were alleviated by Met. Our findings could be significant for understanding or revisiting the risk-benefit evaluation of sitagliptin in type 2 diabetics, and especially those who are known to consume atherogenic diets.
- Published
- 2024
- Full Text
- View/download PDF
13. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders.
- Author
-
Li, Yazhou, Vaughan, Kelli L., Wang, Yun, Yu, Seong-Jin, Bae, Eun-Kyung, Tamargo, Ian A., Kopp, Katherine O., Tweedie, David, Chiang, Cheng-Chuan, Schmidt, Keith T., Lahiri, Debomoy K., Tones, Michael A., Zaleska, Margaret M., Hoffer, Barry J., Mattison, Julie A., and Greig, Nigel H.
- Subjects
CD26 antigen ,ORAL drug administration ,PARKINSON'S disease ,CENTRAL nervous system ,NEURODEGENERATION - Abstract
The endogenous incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) possess neurotrophic, neuroprotective, and anti-neuroinflammatory actions. The dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin reduces degradation of endogenous GLP-1 and GIP, and, thereby, extends the circulation of these protective peptides. The current nonhuman primate (NHP) study evaluates whether human translational sitagliptin doses can elevate systemic and central nervous system (CNS) levels of GLP-1/GIP in naive, non-lesioned NHPs, in line with our prior rodent studies that demonstrated sitagliptin efficacy in preclinical models of Parkinson's disease (PD). PD is an age-associated neurodegenerative disorder whose current treatment is inadequate. Repositioning of the well-tolerated and efficacious diabetes drug sitagliptin provides a rapid approach to add to the therapeutic armamentarium for PD. The pharmacokinetics and pharmacodynamics of 3 oral sitagliptin doses (5, 20, and 100 mg/kg), equivalent to the routine clinical dose, a tolerated higher clinical dose and a maximal dose in monkey, were evaluated. Peak plasma sitagliptin levels were aligned both with prior reports in humans administered equivalent doses and with those in rodents demonstrating reduction of PD associated neurodegeneration. Although CNS uptake of sitagliptin was low (cerebrospinal fluid (CSF)/plasma ratio 0.01), both plasma and CSF concentrations of GLP-1/GIP were elevated in line with efficacy in prior rodent PD studies. Additional cellular studies evaluating human SH-SY5Y and primary rat ventral mesencephalic cultures challenged with 6-hydroxydopamine, established cellular models of PD, demonstrated that joint treatment with GLP-1 + GIP mitigated cell death, particularly when combined with DPP-4 inhibition to maintain incretin levels. In conclusion, this study provides a supportive translational step towards the clinical evaluation of sitagliptin in PD and other neurodegenerative disorders for which aging, similarly, is the greatest risk factor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.
- Author
-
Yu, Seong-Jin, Wang, Yun, Shen, Hui, Bae, Eun-Kyung, Li, Yazhou, Sambamurti, Kumar, Tones, Michael A., Zaleska, Margaret M., Hoffer, Barry J., and Greig, Nigel H.
- Subjects
PARKINSON'S disease ,CD26 antigen ,LABORATORY rats ,TYPE 2 diabetes ,SUBSTANTIA nigra - Abstract
Epidemiological studies report an elevated risk of Parkinson's disease (PD) in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed dipeptidyl peptidase 4 (DPP-4) inhibitors. With an objective to characterize clinically translatable doses of DPP-4 inhibitors (gliptins) in a well-characterized PD rodent model, sitagliptin, PF-00734,200 or vehicle were orally administered to rats initiated either 7-days before or 7-days after unilateral medial forebrain bundle 6-hydroxydopamine (6-OHDA) lesioning. Measures of dopaminergic cell viability, dopamine content, neuroinflammation and neurogenesis were evaluated thereafter in ipsi- and contralateral brain. Plasma and brain incretin and DPP-4 activity levels were quantified. Furthermore, brain incretin receptor levels were age-dependently evaluated in rodents, in 6-OHDA challenged animals and human subjects with/without PD. Cellular studies evaluated neurotrophic/neuroprotective actions of combined incretin administration. Pre-treatment with oral sitagliptin or PF-00734,200 reduced methamphetamine (meth)-induced rotation post-lesioning and dopaminergic degeneration in lesioned substantia nigra pars compacta (SNc) and striatum. Direct intracerebroventricular gliptin administration lacked neuroprotective actions, indicating that systemic incretin-mediated mechanisms underpin gliptin-induced favorable brain effects. Post-treatment with a threefold higher oral gliptin dose, likewise, mitigated meth-induced rotation, dopaminergic neurodegeneration and neuroinflammation, and augmented neurogenesis. These gliptin-induced actions associated with 70–80% plasma and 20–30% brain DPP-4 inhibition, and elevated plasma and brain incretin levels. Brain incretin receptor protein levels were age-dependently maintained in rodents, preserved in rats challenged with 6-OHDA, and in humans with PD. Combined GLP-1 and GIP receptor activation in neuronal cultures resulted in neurotrophic/neuroprotective actions superior to single agonists alone. In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Enzymatic Routes for Chiral Amine Synthesis: Protein Engineering and Process Optimization
- Author
-
Vikhrankar SS, Satbhai S, Kulkarni P, Ranbhor R, Ramakrishnan V, and Kodgire P
- Subjects
chiral amines ,biocatalysis ,protein engineering ,ω-transaminases ,sitagliptin ,enzyme immobilization ,co-factor regeneration ,Medicine (General) ,R5-920 - Abstract
Sayali Shantaram Vikhrankar,1 Seema Satbhai,2 Priyanka Kulkarni,2 Ranjit Ranbhor,3 Vibin Ramakrishnan,4 Prashant Kodgire1 1Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, MP, India; 2Sevit Healthcare Private Limited, Pune, MH, India; 3Pergament & Cepeda LLP, Florham Park, NJ, USA; 4Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, IndiaCorrespondence: Ranjit Ranbhor, Pergament & Cepeda LLP, 25A Hanover Road, Florham Park, NJ, 07932, USA, Tel +1 973 967 0490, Email ranjitranbhor@gmail.comAbstract: Chiral amines are essential motifs in pharmaceuticals, agrochemicals, and specialty chemicals. While traditional chemical routes to chiral amines often lack stereoselectivity and require harsh conditions, biocatalytic methods using engineered enzymes can offer high efficiency and selectivity under sustainable conditions. This review discusses recent advances in protein engineering of transaminases, oxidases, and other enzymes to improve catalytic performance. Strategies such as directed evolution, immobilization, and computational redesign have expanded substrate scope and enhanced efficiency. Furthermore, process optimization guided by techno-economic assessments has been crucial for establishing viable biomanufacturing routes. Combining state-of-the-art enzyme engineering with multifaceted process development will enable scalable, economical enzymatic synthesis of diverse chiral amine targets.Keywords: chiral amines, biocatalysis, protein engineering, ω-transaminases, sitagliptin, enzyme immobilization, co-factor regeneration
- Published
- 2024
16. The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
- Author
-
Shuyan Gu, Jinghong Gu, Xiaoyong Wang, Xiaoling Wang, Lu Li, Hai Gu, and Biao Xu
- Subjects
Cost-effectiveness ,Semaglutide ,Sitagliptin ,Type 2 diabetes ,China ,Medicine (General) ,R5-920 - Abstract
Abstract Background To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform healthcare decision making. Methods The Cardiff diabetes model which is a Monte Carlo micro-simulation model was used to project short-term effects of once-weekly semaglutide versus sitagliptin into long-term outcomes. Short-term data of patient profiles and treatment effects were derived from the 30-week SUSTAIN China trial, in which 868 type 2 diabetes patients with a mean age of 53.1 years inadequately controlled on metformin were randomized to receive once-weekly semaglutide 0.5 mg, once-weekly semaglutide 1 mg, or sitagliptin 100 mg. Costs and quality-adjusted life years (QALYs) were estimated from a healthcare system perspective at a discount rate of 5%. Univariate sensitivity analysis, scenario analysis, and probabilistic sensitivity analysis were conducted to test the uncertainty. Results Over patients’ lifetime projections, patients in both once-weekly semaglutide 0.5 mg and 1 mg arms predicted less incidences of most vascular complications, mortality, and hypoglycemia, and lower total costs compared with those in sitagliptin arm. For an individual patient, compared with sitagliptin, once-weekly semaglutide 0.5 mg conferred a small QALY improvement of 0.08 and a lower cost of $5173, while once-weekly semaglutide 1 mg generated an incremental QALY benefit of 0.12 and a lower cost of $7142, as an add-on to metformin. Therefore, both doses of once-weekly semaglutide were considered dominant versus sitagliptin with more QALY benefits at lower costs. Conclusion Once-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China.
- Published
- 2024
- Full Text
- View/download PDF
17. Sitagliptin ameliorates L-arginine-induced acute pancreatitis via modulating inflammatory cytokines expression and combating oxidative stress.
- Author
-
Eltahir, Heba M., Elbadawy, Hossein M., Almikhlafi, Mohannad A., Alalawi, Ali M., Aldhafiri, Ahmed J., Alahmadi, Yaser M., Al thagfan, Sultan S., Albadrani, Muayad, Eweda, Saber M, and Abouzied, Mekky M.
- Subjects
OXIDATIVE stress ,SITAGLIPTIN ,PANCREATITIS ,HEMATOXYLIN & eosin staining ,CYTOKINES ,PANCREATIC enzymes - Abstract
Background: Acute pancreatitis (AP) is an inflammatory condition that resolves spontaneously, but occasionally, develops into systemic inflammation, organ failure and mortality. Oxidative stress and activation of inflammatory pathways represent major players in AP pathogenesis. Current management of AP relies on attenuating injuries to the pancreas and putting the inflammatory process under control. In this study, we investigated the role of sitagliptin in modulating L-arginine-induced AP in rats. Methods: Swiss rats were subdivided into a healthy control group, AP group (a single dose of L-arginine 250 mg/100 g, intraperitoneal), and sitagliptin + L-arginine-treated group (10 mg sitagliptin/kg body weight/day, orally). Sitagliptin treatment started 1 hour after L-arginine injection and continued for 3days. Biochemical and histopathological investigations were performed on serum and tissue samples collected from test animals. Results: L-arginine increased pancreatic meyloperoxidase and serum amylaseand lipase activities and serum levels of TNF-α, LT-α, IFN-γ, IL-1α/β, IL-6, IL-10, IL-12, and IL-15. AP animals showed elevated MDA and NO and decreased GSH and serum calcium levels. Histopathological changes were observed by H&E staining. Sitagliptin treatment significantly ameliorated these biochemical and histological changes diminishing the signs of AP. Conclusion: Sitagliptin treatmentwas effective in ameliorating L-arginine-induced AP which can be regarded to its anti-inflammatory and antioxidant effect. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.
- Author
-
Qianyu Lv, Yingtian Yang, Yanfei Lv, Qian Wu, Xinzheng Hou, Lanlan Li, Xuejiao Ye, Chenyan Yang, and Shihan Wang
- Subjects
CAROTID intima-media thickness ,SITAGLIPTIN ,METFORMIN ,HYPOGLYCEMIC agents ,DRUGS ,EXENATIDE ,ROSIGLITAZONE - Abstract
Objective: The progression of carotid intima-media thickness (cIMT) can partially predict the occurrence of future cardiovascular events. This network meta-analysis compared the effects of 14 antidiabetic drugs (acarbose, alogliptin, exenatide, glibenclamide, glimepiride, ipragliflozin, metformin, nateglinide, pioglitazone, rosiglitazone, sitagliptin, tofoglifozin, troglitazone, voglibose) on the progression of cIMT. Method: PubMed, EMBASE, Cochrane Library, and Web of Science were searched to screen all clinical trials of treatment of cIMT with hypoglycemic agents before March 1, 2024. The differences in the changes in cIMT between the treatment group and control group were evaluated. Result: After screening 8395 citations, 25 studies (6675 patients) were included. The results indicated that exenatide had the best efficacy in slowing down cIMT progress, and exenatide [MD=-0.13,95%CI (-0.25, -0.01)], alogliptin [MD=-0.08,95%CI (-0.13, -0.02)] and metformin [MD=-0.05, 95%CI (-0.09, -0.02)] are more effective than placebo. Conclusion: Long-term treatment of exenatide, alogliptin, and metformin may be more effective than other hypoglycemic drugs in slowing the progression of cIMT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Miniature mass spectrometer–based point-of-care assay for quantification of metformin and sitagliptin in human blood and urine.
- Author
-
Chen, Jingying, Li, Yaohan, Chen, Jingjing, Wang, Ruimin, Lu, Miaoshan, and Yu, Changbin
- Subjects
- *
MASS spectrometers , *MEDICAL personnel , *URINE , *SITAGLIPTIN , *METFORMIN , *TYPE 2 diabetes , *POINT-of-care testing - Abstract
Metformin (MET) and sitagliptin (STG) are widely used as the first-line and long-term oral hypoglycemic agents for managing type 2 diabetes mellitus (T2DM). However, the current lack of convenient and rapid measurement methods poses a challenge for individualized management. This study developed a point-of-care (POC) assay method utilizing a miniature mass spectrometer, enabling rapid and accurate quantification of MET and STG concentrations in human blood and urine. By combining the miniature mass spectrometer with paper spray ionization, this method simplifies the process into three to four steps, requires minimal amounts of bodily fluids (50 μL of blood and 2 μL of urine), and is able to obtain quantification results within approximately 2 min. Stable isotope-labeled internal standards were employed to enhance the accuracy and stability of measurement. The MS/MS responses exhibited good linear relationship with concentration, with relative standard deviations (RSDs) below 25%. It has the potential to provide immediate treatment feedback and decision support for patients and healthcare professionals in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries—A Cross-Sectional Comparison.
- Author
-
Atănăsoie, Ana-Maria, Ancuceanu, Robert Viorel, Krajnović, Dušanka, Waszyk-Nowaczyk, Magdalena, Skotnicki, Marcin, Tondowska, Dorota, Petrova, Guenka, Niculae, Andrei Marian, and Tăerel, Adriana-Elena
- Subjects
- *
HYPOGLYCEMIC agents , *INSULIN , *MEDICAL personnel , *SITAGLIPTIN , *RETAIL industry , *GLUCAGON-like peptide-1 agonists - Abstract
Diabetes mellitus is a complex, multifactorial, progressive condition with a variety of approved therapeutic options. The purpose of this study was to offer an overview of the authorized antidiabetic medicines (excluding insulin) compared with marketed products in seven European countries. Data were obtained from primary sources, including the websites of national authorities and directly from specialists in the countries of interest. The range of marketed medicines compared with the authorized group was assessed in terms of active pharmaceutical ingredients (>60% in Bulgaria, France, Serbia), brand names (>70% in Bulgaria, the Czech Republic, Romania, Serbia, Spain), pharmaceutical forms (>60% in all countries), strengths (>60% in Bulgaria, the Czech Republic, Romania, Serbia, Spain), marketing authorization holder (≥50% in all countries) and the status of medicine. Spain was found to have the highest number of products based on most of these attributes. Over 90% of authorized medicines had a pharmacy price in Serbia. Regarding the newer class of GLP-1 receptor agonists, a retail price for all approved substances was available in Bulgaria, Romania, Serbia, and Spain. Only one brand name with one concentration was found available for some agents, being susceptible to drug shortages: glibenclamide (Romania, Serbia, Spain), glipizide (the Czech Republic, Poland, Romania, Spain), glisentide (Spain), acarbose (the Czech Republic), sitagliptin (Bulgaria, Poland), vildagliptin (the Czech Republic, Poland) and saxagliptin (the Czech Republic, France, Romania, Serbia). An overview of the national and international therapeutic options may allow competent authorities and health professionals to take rapid measures in case of supply problems or health crises. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. EU legal and regulatory update May 2024.
- Subjects
- *
SITAGLIPTIN , *COVID-19 vaccines , *PATENT offices , *CLINICAL trials , *CONDUCT of life , *INTERFERON beta 1b - Abstract
This document provides a legal and regulatory update for May 2024 in the European Union (EU) regarding pharmaceutical patents and market authorizations. It highlights specific cases, such as the invalidity of Novartis' patent for fingolimod, the injunction against generic versions of sitagliptin and metformin, and the rejection of a SPC application for avelumab. The document also mentions the dismissal of requests to cancel market authorizations for the Spikevas and Cominarty COVID-19 vaccines. It discusses two separate cases related to the commercialization of medical products, one involving Mylan Ireland and the other involving Doctipharma SAS. The document further examines a complicated judgment regarding the procedure used by the European Medicines Agency (EMA) to designate its experts, as well as a judgment under appeal regarding the interpretation of a policy on competing interests in the pharmaceutical industry. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
22. Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test.
- Author
-
Beitelshees, Amber L., Streeten, Elizabeth A., Shahidzadeh Yazdi, Zhinous, Whitlatch, Hilary B., Mitchell, Braxton D., Shuldiner, Alan R., Montasser, May E., and Taylor, Simeon I.
- Subjects
- *
SITAGLIPTIN , *GLUCOSE tolerance tests , *GESTATIONAL diabetes , *DRUG side effects , *INSULIN , *SECRETION , *TYPE 2 diabetes - Abstract
DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses. Sitagliptin (100 mg) was administered to 47 healthy volunteers. Several endpoints were measured to assess clinically relevant responses – including the effect of sitagliptin on glucose and insulin levels during an oral glucose tolerance test (OGTT). This pilot study confirmed that sitagliptin (100 mg) decreased the area under the curve for glucose during an OGTT (p = 0.0003). Furthermore, sitagliptin promoted insulin secretion during the early portion of the OGTT as reflected by an increase in the ratio of plasma insulin at 30 min divided by plasma insulin at 60 min (T30:T60) from mean ± SEM 0.87 ± 0.05 to 1.62 ± 0.36 mU/L (p = 0.04). The magnitude of sitagliptin's effect on insulin secretion (as judged by the increase in the T30:T60 ratio for insulin) was correlated with the magnitude of sitagliptin‐induced increase in the area under the curve for intact plasma GLP1 levels during the first hour of the OGTT. This study confirmed previously reported sex differences in glucose and insulin levels during an OGTT. Specifically, females exhibited higher levels of glucose and insulin at the 90–180 min time points. However, we did not detect significant sex‐associated differences in the magnitude of sitagliptin‐induced changes in T30:T60 ratios for either glucose or insulin. In conclusion, T30:T60 ratios for insulin and glucose during an OGTT provide useful indices to assess pharmacodynamic responses to DPP4 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. An efficient RP-HPLC-based approach for simultaneous determination of sitagliptin and metformin HCl in pharmaceutical drug formulation.
- Author
-
Ali, Mohsin, Shah, Muhammad Raza, Zairov, Rustem, Zafar, Shaista, Ali, Syed Imran, Ansar, Faizan, Uddin, Khadim Mohi, and Akylbekov, Nurgali
- Abstract
This study introduces an innovative, and rapid HPLC method using reverse phase elution for the simultaneous analysis of Sitagliptin and Metformin HCl in pharmaceutical formulations. This combination was explored in bulk and solid dosage forms using Luna Phenomenex C8 column (4.6 x 250 mm, 5 µm) at ambient temperature in isocratic elution. It was found that the mobile phase comprising of 0.1% ortho-phosphoric acid, potassium dihydrogen phosphate buffer (pH 3.0) and acetonitrile in ratios 35:35:30, showed a symmetrical peak for Sitagliptin and Metformin HCl. The detection was carried out at 210nm, using a flow rate of 1.0mL/min. The method was linear over the concentration range for Sitagliptin 2.5-7.5 ppm and Metformin HCl 25-75 ppm. The assay recoveries of Sitagliptin and Metformin were found to be 100.36% and 100.20%, respectively. The LOD and LOQ for the Sitagliptin were found to be 0.201 ppm and 0.301 ppm and for Metformin HCl 0.101 ppm and 0.303 ppm, respectively. The proposed methods can be implemented for controlling quality in bulk and solid dosage forms. The analytical methods were validated as per the guideline of ICH Q2 (R2). The developed HPLC methods were effectively employed for the determination of combined dosage forms in pharmaceutical formulations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Bioanalytical Method Development and Validation and forced degradation of Sitagliptin and determination of Pharmacokinetic application study in Human Plasma by RP-HPLC method.
- Author
-
Shanmuga Kumar, S. D., Kotte, Mahendar, Rao, N. Keerthana, Jyothi, Vollem, Pavani, Juttu, Shivani, Ashritha, and Sundar, P. Shyam
- Subjects
HIGH performance liquid chromatography ,SITAGLIPTIN ,PHARMACOKINETICS ,HUMAN experimentation ,STATISTICAL sampling - Abstract
In the present investigation, an attempt was made for the development, validation, forced degradation and pharmacokinetic application of sitagliptin in the human plasma spiking studies by UV - HPLC method. The experimentation was developed based on the extensive literature survey and ascertained by the statistical parameters of the sampling. A simplified, accurate method was created by the liquid chromatographic system from Shimadazu LC 20AD consisting of manual injection. The optimized chromatogram was obtained with acetonitrile in the isocratic mobile phase method at a 1.0 mL/min flow rate. A thermo C-8 column (4.6X250mm,5μm) was used as a stationary phase, and 265.0nm was selected as the detection wavelength with the aid of a UV-Vis detector. The proposed method was validated as per ICH guidelines. The technique was linear in the range of 10-50μg/mL with correlation coefficient R2 = 0.9746, respectively. Recovery studies postulated that % RSD 19.14, 3 & 9.95 respectively. Injection repeatability values were found to be % RSD 17 & 10.63 for intraday and interday, respectively. Stress degradation studies revealed that sitagliptin degrades more rapidly when subjected to 0.1 NaoH. Human plasma spiking studies reported 3.02 ng/mL at 3.02+/-60 min of C and T max, respectively [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Synergistic Antitumor and Apoptotic Activity of Sitagliptin or Linagliptin Plus Cisplatin Against A549 Lung Cancer Cells (An Invitro Study).
- Author
-
Al Khafaji, Ameer M. and Bairam, Ahsan F.
- Subjects
ANTINEOPLASTIC agents ,SITAGLIPTIN ,LUNG cancer ,CANCER cells ,LINAGLIPTIN - Abstract
Objective: Lung cancer (LC) has the highest mortality rate globally. Most chemotherapeutic medicines now in use are cytotoxic, prompting the search for novel compounds with anticancer properties and improved safety profiles for normal cells. Dipeptidyl peptidase-4 inhibitors have demonstrated anticancer effects and apoptotic properties by specifically inhibiting dipeptidyl peptidase-4, a glycoprotein found in various organs that support the spread of cancer and tumor formation. Based on that, this study aimed to evaluate the cytotoxicity and apoptotic activity of sitagliptin (SITA) and linagliptin (LINA) against the lung cancer cell line (A549) alone and in combination with cisplatin (CP). Methods: A549 cells were categorized into six groups: control (untreated cells), CP-treated cells, SITA-treated cells, LINA-treated cells, CP plus SITA treated cells (1:1 ratio), and CP plus LINA treated cells (1:1 ratio). After 72 hours of incubation, cell viability (or cytotoxicity) and concentration required to inhibit 50% of cell viability (IC50) for each group were determined using an MTT assay. This method is safe and easy to use, has more reproducibility, and is commonly used for cell viability and cytotoxicity tests. Later, A549 cells were cultured in six flasks and exposed to the IC50 for 36 hours. Afterward, the cells were harvested and centrifuged, and the supernatant was removed. The remaining cell pellets were collected and lysed using a lysis buffer to measure B-cell lymphoma type 2 (BCL-2) levels with ELISA test kits. The data was collected and subjected to statistical analysis techniques. Results: MTT assay results determined that SITA and LINA significantly increased A549 cell cytotoxicity compared to the control group (P<0.0001). Moreover, combining SITA or LINA with CP showed markedly increased antitumor efficacy and more significant cytotoxicity directed toward A549 cells. Additionally, these combinations highly reduced IC50 in comparison to monotherapy. Considerably, both drugs showed remarkable apoptotic activity on A549 cells when used alone or combined with CP by decreasing BCL2 levels. Consequently, it potentiates apoptotic effects and cytotoxicity of CP against cancer cells. Interestingly, Lina was more potent than Sita regarding cytotoxicity and apoptotic activity on A549 cells. Conclusion: SITA and Lina exhibited significant cytotoxic and apoptotic effects against A549 cells through the induction of apoptosis. Notably, the results suggest a potential synergistic anticancer impact on CP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study).
- Author
-
Al Khafaji, Ameer M. and Bairam, Ahsan F.
- Subjects
ANTINEOPLASTIC agents ,ANTIOXIDANTS ,SITAGLIPTIN ,LINAGLIPTIN ,CANCER cell growth - Abstract
Lung cancer has the highest global fatality rate of all cancers, and most existing therapies have a wide range of toxic effects. This necessitates searching for new medications with potential anticancer properties and a better safety profile against normal cells. Dipeptidyl peptidase-4 (DPP4) inhibitors have recently shown anticancer efficacy in various malignancies such as colorectal, prostate, and renal cancer. Therefore, this study investigated the anticancer activity of sitagliptin (SITA) and linagliptin (LINA) against the lung cancer cell line A549 alone and in combination with cisplatin (CP). A549 cells were divided into six groups: control (untreated cells), CP-treated cells, SITA-treated cells, LINA-treated cells, CP plus SITA-treated cells (ratio 1:1), and CP plus LINA-treated cells (ratio 1:1). After 72 hours of incubation, a 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) test was used to determine cell viability and the concentration of 50% inhibition for cell viability (IC
50 ) for each group. A549 cells were later seeded in six flasks and treated with the resulting IC50 ; cell pellets were collected and lysed to determine the malondialdehyde (MDA) level using ELISA kits. SITA and LINA therapy dramatically reduced A549 cell viability compared to the control (P < 0.0001), with results comparable to CP. When SITA and LINA were combined with CP, they demonstrated significantly higher anticancer efficacy than when used alone. Notably, both medicines lowered MDA levels when taken alone or in combination with CP. SITA and LINA showed promising anticancer and antioxidant activity against A549 cells. This may indicate a potential synergistic anticancer effect with CP. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
27. Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.
- Author
-
Pitts, Mason A., Griggs, Ryanne H., Hall, Macey R., Tankersley, McKinley S., and Johnson, Jeremy L.
- Subjects
DRUG dosage ,GLUCAGON-like peptide-1 agonists ,GLYCOSYLATED hemoglobin ,GLYCEMIC control ,INSULIN derivatives ,SITAGLIPTIN ,DRUG therapy ,APPETITE ,LINAGLIPTIN ,TREATMENT effectiveness ,INSULIN aspart ,TYPE 2 diabetes - Abstract
The article describes two case scenarios in which liraglutide demonstrated glucose lowering similar to agents categorized as having very high efficacy. A 63-year-old Black man was referred to an outpatient clinic's in-house pharmacist-run diabetes education and management service while a 63-year-old White man was referred to the same clinical pharmacy service. The cases show the potential for robust A1C lowering with the use of liraglutide in patients with type 2 diabetes who overeat.
- Published
- 2024
- Full Text
- View/download PDF
28. Exploring the Anticancer and Antioxidant Potential Effects of Sitagliptin: An In Vitro Study on Lung Cancer Cell Lines.
- Author
-
Al Khafaji, Ameer M., Bairam, Ahsan F., and Abbas, Shaymaa F.
- Subjects
CANCER cell growth ,CD26 antigen ,SITAGLIPTIN ,RENAL cancer ,CISPLATIN - Abstract
Lung cancer possesses the most significant worldwide mortality rate among all types of tumors, and the majority of current treatments exhibit a broad spectrum of adverse reactions. This requires investigating novel drugs that can inhibit the growth of cancer cells while minimizing harm to normal cells. Recent studies have demonstrated that Dipeptidyl peptidase-4 (DPP4) inhibitors can effectively suppress the growth of cancer cells in several types of malignancies, including colorectal, prostate, and kidney cancers. Hence, this study evaluated the effectiveness of sitagliptin in suppressing the proliferation of lung carcinoma cells (A549) alone as well as in conjunction with cisplatin. A549 cells were divided into four groups: control (untreated cells), cells treated with cisplatin, cells treated with sitagliptin, and cells treated with cisplatin plus sitagliptin combination (ratio 1:1). After incubation for 72 hours, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl2H-tetrazolium bromide (MTT) test was utilized to evaluate cell viability percent and concentration of 50% inhibition for cell viability (IC50) for each group. Then, A549 cells were cultured into four flasks and exposed to the IC50 concentration. The resulting cell pellets were gathered and subjected to lysis to assess the malondialdehyde (MDA) level using ELISA kits. The vitality of A549 cells was significantly reduced by Sitagliptin therapy compared to the control (P < 0.0001). When the combination of sitagliptin and cisplatin was administered, it exhibited markedly superior anticancer effectiveness compared to their usage alone. Significantly, sitagliptin reduced MDA levels, whether used individually or in combination with cisplatin. As a result, sitagliptin exhibited significant anticancer and antioxidant properties against A549 cells. This suggests a possible synergistic anticancer effect with cisplatin. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication.
- Author
-
Ikramov, Alisher, Mukhtarova, Shakhnoza, Trigulova, Raisa, Alimova, Dilnoza, and Abdullaeva, Saodat
- Subjects
GLYCOSYLATED hemoglobin ,TYPE 2 diabetes ,CARDIOVASCULAR diseases ,GLYCEMIC control ,SUPPORT vector machines ,FEATURE selection - Abstract
Blood glycosylated hemoglobin level can be affected by various factors in patients with type 2 diabetes and cardiovascular diseases. Frequent measurements are expensive, and a suitable estimation method could improve treatment outcomes. Patients and methods: 93 patients were recruited in this research. We analyzed a number of parameters such as age, glucose level, blood pressure, Body Mass Index, cholesterol level, echocardiography et al. Patients were prescribed metformin. One group (n=60) additionally was taking sitagliptin. We applied eight machine learning methods (k nearest neighbors, Random Forest, Support Vector Machine, Extra Trees, XGBoost, Linear Regression including Lasso, and ElasticNet) to predict exact values of glycosylated hemoglobin in two years. Results: We applied a feature selection approach using step-by-step removal of them, Linear Regression on remaining features, and Pearson's correlation coefficient on the validation set. As a result, we got four different subsets for each group. We compared all eight Machine Learning methods using different hyperparameters on validation sets and chose the best models. We tested the best models on the external testing set and got R² = 0.88, C Index = 0.857, Accuracy = 0.846, and MAE (Mean Absolute Error) = 0.65 for the first group, R² = 0.86, C Index = 0.80, Accuracy = 0.75, and MAE = 0.41 for the second group. Conclusion: The resulting algorithms could be used to assist clinical decisionmaking on prescribing anti-diabetic medications in pursuit of achieving glycemic control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Ultra‐high‐performance liquid chromatography‐tandem mass spectrometry analytical method for the determination of nitrosamine drug substance‐related impurity in sitagliptin base and salts.
- Author
-
Bessa‐Jambrina, Sergio, Marlés‐Torres, Anna, and Galán‐Rodríguez, Cristóbal
- Subjects
- *
NITROSOAMINES , *ELECTROSPRAY ionization mass spectrometry , *SITAGLIPTIN - Abstract
A reversed‐phase ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method is presented for the quantification of the mutagenic impurity 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro‐[1,2,4]triazolo[4,3‐a]pyrazine found in three sitagliptin drug substances (sitagliptin base [SG], sitagliptin hydrochloride monohydrate [SG HCl{H}] salt, and sitagliptin phosphate monohydrate [SG P{H}] salt). A simple and highly sensitive method was developed for SG, SG HCl(H) salt, and SG P(H) salt. Sample preparation was adapted to each product considering solubility, sensitivity, and accuracy issues. Chromatographic separation was achieved using an Acquity HSS T3 column (3.0 × 100 mm, 1.8 μm) and a mobile phase consisting of formic acid 0.1% in water combined with methanol. Detection and quantification of the impurity were carried out using triple quadrupole mass spectrometry detection with electrospray ionization in the multiple reaction monitoring mode. The limit of detection and limit of quantification was found to be 0.1–0.3 and 10 ppb, respectively. The accuracy and precision of the method were satisfactorily determined with recovery values between 74.1% and 119.4%. Linearity is demonstrated in the range of 10 and 2000 ppb with regression coefficients (R) within the range of 0.9918–0.9972. The method is currently used for the analysis of the mutagenic impurity in the three‐drug substances in the Moehs Group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
- Author
-
Rasouli, Neda, Younes, Naji, Ghosh, Alokananda, Albu, Jeanine, Cohen, Robert M., DeFronzo, Ralph A., Diaz, Elsa, Sayyed Kassem, Laure, Luchsinger, José A., McGill, Janet B., Sivitz, William I., Tamborlane, William V., Utzschneider, Kristina M., Kahn, Steven E., Crandall, J.P., McKee, M.D., Behringer-Massera, S., Brown-Friday, J., Xhori, E., and Ballentine-Cargill, K.
- Subjects
- *
GLUCOSE tolerance tests , *TYPE 2 diabetes , *INSULIN sensitivity , *DRUGS , *CLINICAL trials , *SITAGLIPTIN - Abstract
OBJECTIVE: To compare the long-term effects of glucose-lowering medications (insulin glargine U-100, glimepiride, liraglutide, and sitagliptin) when added to metformin on insulin sensitivity and β-cell function. RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) cohort with type 2 diabetes (n = 4,801), HOMA2 was used to estimate insulin sensitivity (HOMA2-%S) and fasting β-cell function (HOMA2-%B) at baseline and 1, 3, and 5 years on treatment. Oral glucose tolerance test β-cell responses (C-peptide index [CPI] and total C-peptide response [incremental C-peptide/incremental glucose over 120 min]) were evaluated at the same time points. These responses adjusted for HOMA2-%S in regression analysis provided estimates of β-cell function. RESULTS: HOMA2-%S increased from baseline to year 1 with glargine and remained stable thereafter, while it did not change from baseline in the other treatment groups. HOMA2-%B and C-peptide responses were increased to variable degrees at year 1 in all groups but then declined progressively over time. At year 5, CPI was similar between liraglutide and sitagliptin, and higher for both than for glargine and glimepiride [0.80, 0.87, 0.74, and 0.64 (nmol/L)/(mg/dL) * 100, respectively; P < 0.001], while the total C-peptide response was greatest with liraglutide, followed in descending order by sitagliptin, glargine, and glimepiride [1.54, 1.25, 1.02, and 0.87 (nmol/L)/(mg/dL) * 100, respectively, P < 0.001]. After adjustment for HOMA2-%S to obtain an estimate of β-cell function, the nature of the change in β-cell responses reflected those in β-cell function. CONCLUSIONS: The differential long-term effects on insulin sensitivity and β-cell function of four different glucose-lowering medications when added to metformin highlight the importance of the loss of β-cell function in the progression of type 2 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.
- Author
-
Gu, Shuyan, Gu, Jinghong, Wang, Xiaoyong, Wang, Xiaoling, Li, Lu, Gu, Hai, and Xu, Biao
- Subjects
TYPE 2 diabetes ,SEMAGLUTIDE ,PEOPLE with diabetes ,SITAGLIPTIN ,QUALITY-adjusted life years ,COST effectiveness ,BRIEF psychotherapy - Abstract
Background: To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform healthcare decision making. Methods: The Cardiff diabetes model which is a Monte Carlo micro-simulation model was used to project short-term effects of once-weekly semaglutide versus sitagliptin into long-term outcomes. Short-term data of patient profiles and treatment effects were derived from the 30-week SUSTAIN China trial, in which 868 type 2 diabetes patients with a mean age of 53.1 years inadequately controlled on metformin were randomized to receive once-weekly semaglutide 0.5 mg, once-weekly semaglutide 1 mg, or sitagliptin 100 mg. Costs and quality-adjusted life years (QALYs) were estimated from a healthcare system perspective at a discount rate of 5%. Univariate sensitivity analysis, scenario analysis, and probabilistic sensitivity analysis were conducted to test the uncertainty. Results: Over patients' lifetime projections, patients in both once-weekly semaglutide 0.5 mg and 1 mg arms predicted less incidences of most vascular complications, mortality, and hypoglycemia, and lower total costs compared with those in sitagliptin arm. For an individual patient, compared with sitagliptin, once-weekly semaglutide 0.5 mg conferred a small QALY improvement of 0.08 and a lower cost of $5173, while once-weekly semaglutide 1 mg generated an incremental QALY benefit of 0.12 and a lower cost of $7142, as an add-on to metformin. Therefore, both doses of once-weekly semaglutide were considered dominant versus sitagliptin with more QALY benefits at lower costs. Conclusion: Once-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus.
- Author
-
Ray, Soumitra, Ezhilan, J., Karnik, Rajiv, Prasad, Ashish, and Dhar, Rajashree
- Subjects
STROKE prevention ,HEART failure risk factors ,ATHEROSCLEROSIS risk factors ,ATRIAL fibrillation prevention ,COMBINATION drug therapy ,MEDICAL protocols ,MYCOSES ,MYOCARDIAL infarction ,DAPAGLIFLOZIN ,SITAGLIPTIN ,MAJOR adverse cardiovascular events ,GENITAL diseases ,BODY weight ,GLYCEMIC control ,CLINICAL trials ,TREATMENT effectiveness ,DECISION making in clinical medicine ,CARDIOVASCULAR diseases risk factors ,HEART failure ,CHRONIC kidney failure ,TYPE 2 diabetes ,PERCUTANEOUS coronary intervention ,COMORBIDITY ,HYPOGLYCEMIA ,DISEASE risk factors ,DISEASE complications - Abstract
Type 2 diabetes mellitus (T2DM) is known to be associated with macrovascular (coronary heart disease, stroke, and peripheral arterial disease) and microvascular complications (diabetic kidney disease, retinopathy, and peripheral neuropathy). The coexistence of T2DM with established/risk of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease confers a poor prognosis, and management can be challenging. Guidelines recommend clinicians to consider CV/HF risk, renal/hepatic risk, and other comorbidities while choosing an antidiabetic regimen. The fixed dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors provides both glycemic and pleiotropic effects, including lower risk of hypoglycemia, lower rates of genitourinary tract infections, and weight neutrality. Based on CV risk, including HF, the combination of SGLT2i and DPP4i may be preferred over other conventional therapies (those with no CV benefit) in cases of established CV disease and/or HF risk. The Indian expert consensus group discussed the literature, clinical benefits, and the role of the FDC of Dapagliflozin and Sitagliptin for the unmet cardiovascular benefits in T2DM patients. This practical guidance document would support general physicians, endocrinologists, diabetologists, cardiologists, and nephrologists in selecting the appropriate regimen for superior patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
- Author
-
Pankaj M. Kharabe, Prasad P. Jumade, Pravin N. Khatale, Parimal P. Katolkar, Santosh R. Butle, Mahendra D. Kshirsagar, Vishal V. Pendharkar, Amol V. Sawale, and Kalyani S. Choudhari
- Subjects
Dipeptidyl peptidase-4 inhibitors ,Evogliptin ,Sitagliptin ,Saxagliptin ,Vildagliptin ,Linagliptin ,Analytical chemistry ,QD71-142 - Abstract
Separation and quantification of highly polar metformin (MTF) alone or in combination with dipeptidyl peptidase-4 inhibitors, such as evogliptin (EVG), sitagliptin, saxagliptin, vildagliptin, linagliptin and teneligliptin, specifically from human plasma and pharmaceutical products is still difficult in mostly preferred ODS based RP-HPLC techniques. Since, owing to weak retention of MTF in ODS, it elutes together with the biological fluid components and drug excipients. Therefore, in this study, alternative to ODS based RP-HPLC, comparatively less known analytical techniques like strong cation exchange chromatography (SCX-3), hydrophilic interaction liquid chromatography (HILIC) and mix-mode chromatography (MMC) were comprehensively evaluated for their potentials and limitations in simultaneous quantification of newly approved EVG and MTF combination (Valera-M). In results, prolonged application of SCX-3, exhibits irreproducible and irreversible retention of MTF and EVG. While in HILIC with Cyano column, excessive acetonitrile as eluent developed the precipitation of MTF and column back pressure. Comparatively, the Acclaimed® mix-mode HILIC-1, demonstrated much promising and reproducible results for MTF and EVG separation and importantly, it can be used either reverse phase or HILIC mode. Considering the overall benefits of Acclaimed® mix-mode HILIC-1, it was used in estimation of MTF and EVG from human plasma and pharmaceutical formulations.
- Published
- 2024
- Full Text
- View/download PDF
35. Assessment of Factors Affecting Therapeutic Response of the DPP-4 Inhibitor Sitagliptin in A Sample of Iraqi Type 2 Diabetic Patients
- Author
-
Ahmad Nazar Jawad, Kadhim Ali Kadhim, Qusay Baqer Alzajaji, and Haider Al-Neshmi
- Subjects
Type 2 diabetes ,DPP-4 inhibitors ,Sitagliptin ,Pharmacy and materia medica ,RS1-441 - Abstract
Background: Type 2 diabetes is a complex and diverse disease, and the response to dipeptidyl peptidase-4 inhibitors may exhibit substantial variability between individuals. Several variables may play a role in variances in individual responses to treatment. Objective: The purpose of the research was to assess the degree to which Iraqi patients with type 2 diabetes responded to sitagliptin and to investigate the factors that contribute to sitagliptin's overall efficacy. Patients and methods: Eighty patients with type 2 diabetes who were using sitagliptin (100 mg per day) were included in this observational, cross-sectional study. Sociodemographic and patient clinical data were collected. Glycated hemoglobin (HbA1c), lipid profile parameters, and C-reactive protein were measured. Results: The response rate to sitagliptin was 43.8%. Smokers and hypertensive patients, in addition to those not on diet, had higher HbA1c levels with nearly significant p values than non-smokers, normotensive patients, and those on diet, respectively. Poor response patients had higher levels of total cholesterol and triglycerides. Conclusions: Possible variables that may have influenced the response to sitagliptin include smoking, hypertension, and an unhealthy diet. Furthermore, elevated levels of triglycerides may serve as an indicator of poor response.
- Published
- 2024
- Full Text
- View/download PDF
36. Bioanalytical Method Development and Validation of UV Spectrophotometric Method for Estimation of Sitagliptin in Urine sample
- Author
-
Shinde, G S, Jadhav, R S, Tambe, V B, Kote, R B, and Argade, V P
- Published
- 2024
- Full Text
- View/download PDF
37. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial
- Author
-
Elbarbary, Nancy S., Ismail, Eman A., El-Hamamsy, Manal H., Ibrahim, Marwa Z., and Elkholy, Amal A.
- Published
- 2024
- Full Text
- View/download PDF
38. Development of an ecofriendly thin-layer chromatography‒densitometry method for the simultaneous quantification of dapagliflozin propanediol monohydrate, sitagliptin, and metformin hydrochoride in tablet formulation using analytical ecoscale, GAPI, and AGREE tools
- Author
-
Varghese, Susheel John, Ponmozhi, P., and Ravi, Thengungal Kochupappy
- Published
- 2024
- Full Text
- View/download PDF
39. Repurposing DPP-4 Inhibitors as a Novel Intervention in COVID-19: In Silico Analysis for SARS-CoV-2 Spike Glycoprotein Inhibition
- Author
-
Danta, Chhanda Charan and Mahapatra, Manoj Kumar
- Published
- 2024
- Full Text
- View/download PDF
40. Dapagliflozin combined with sitagliptin in treatment of type 2 diabetes
- Author
-
CHEN Hui, LIN Yuesong, PEI Qin, and ZHAO Lingang
- Subjects
dapagliflozin ,sitagliptin ,type 2 diabetes ,fasting plasma glucose ,glycated hemoglobin ,c-reactive protein ,left ventricular ejection fraction ,blood glucose fluctuations ,Medicine - Abstract
Objective To investigate the efficacy of single drug treatment of dapagliflozin and combination of dapagliflozin and sitagliptin in the treatment of type 2 diabetes mellitus (T2DM). Methods Sixty-two patients with T2DM admitted to Luhe District Hospital of Chinese Medicine from January 2022 to December 2023 were selected as research subjects, and the patients were randomly divided into two groups, with 31 cases in each group. The control group only received treatment with dapagliflozin (10 mg/d oral), while the observation group received both dapagliflozin (10 mg/d oral) and sitagliptin (100 mg/d oral) treatment. Both groups were treated for 3 months. The post-treatment blood glucose control effects [fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c)], blood glucose fluctuations, inflammatory markers [C-reactive protein (CRP)], and cardiac function [left ventricular ejection fraction (LVEF)] were compared between two groups. Results After 3 months of treatment, compared with before treatment, both groups showed a significant decrease in FPG and HbA1c after treatment (P<0.05). Compared with the control group, FPG [(6.96±0.87) mmol/L vs (7.91±0.96) mmol/L, t=4.083, P<0.01] and HbA1c [(6.54±0.33)% vs (7.65±0.58)%, t=9.261, P<0.01] of patients in the observation group were significantly decreased, and the standard deviation of mean blood glucose (SDBG) and amplitude of postprandial blood glucose fluctuation (PPGE) were lower (P
- Published
- 2024
- Full Text
- View/download PDF
41. Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax
- Author
-
Ahmed M. Abd-Eldayem, Sohayla Mahmoud Makram, Basim Anwar Shehata Messiha, Hanan H. Abd-Elhafeez, and Mustafa Ahmed Abdel-Reheim
- Subjects
Cyclosporine ,Sitagliptin ,Hesperidin ,Nephrotoxicity ,Nrf2 ,NF-κB ,Medicine ,Science - Abstract
Abstract Cyclosporine A (CsA) is employed for organ transplantation and autoimmune disorders. Nephrotoxicity is a serious side effect that hampers the therapeutic use of CsA. Hesperidin and sitagliptin were investigated for their antioxidant, anti-inflammatory, and tissue-protective properties. We aimed to investigate and compare the possible nephroprotective effects of hesperidin and sitagliptin. Male Wistar rats were utilized for induction of CsA nephrotoxicity (20 mg/kg/day, intraperitoneally for 7 days). Animals were treated with sitagliptin (10 mg/kg/day, orally for 14 days) or hesperidin (200 mg/kg/day, orally for 14 days). Blood urea, serum creatinine, albumin, cystatin-C (CYS-C), myeloperoxidase (MPO), and glucose were measured. The renal malondialdehyde (MDA), glutathione (GSH), catalase, and SOD were estimated. Renal TNF-α protein expression was evaluated. Histopathological examination and immunostaining study of Bax, Nrf-2, and NF-κB were performed. Sitagliptin or hesperidin attenuated CsA-mediated elevations of blood urea, serum creatinine, CYS-C, glucose, renal MDA, and MPO, and preserved the serum albumin, renal catalase, SOD, and GSH. They reduced the expressions of TNF-α, Bax, NF-κB, and pathological kidney damage. Nrf2 expression in the kidney was raised. Hesperidin or sitagliptin could protect the kidney against CsA through the mitigation of oxidative stress, apoptosis, and inflammation. Sitagliptin proved to be more beneficial than hesperidin.
- Published
- 2024
- Full Text
- View/download PDF
42. Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
- Author
-
Mondal Aashish, Naskar Arindam, Sheelu Shafiq Siddiqi, Deepak Bhosle, V. J. Mallikarjuna, Dange Amol, Sorate Sanket, Gavali Omkar, Patel Parth, Hasnani Dhruvi, Prasad Durga, Dalwadi Pradeep, Kumar Suresh, Pathak Vaishali, Chaudhari Mayura, Basu Indraneel, Shembalkar Jayashri, Fariooqui Arif, S. K. Raghavendra, Varade Deepak, Thakkar Ravindra, Bhanushali Shaishav, Gaikwad Vijay, Kamran Khan, V. V. Mahajani, A. D. Sharma, Mayur Mayabhate, R. R. Pawar, A. S. Aiwale, and Shahavi Vinayaka
- Subjects
Type 2 diabetes mellitus ,IMPACT study ,Pioglitazone ,Metformin ,Sitagliptin ,Triple therapy ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Due to the progressive decline in β-cell function, it is often necessary to utilize multiple agents with complementary mechanisms of action to address various facets and achieve glycemic control. Thus, this study aimed to evaluate the efficacy and safety of a fixed-dose combination (FDC) of metformin/sitagliptin/pioglitazone (MSP) therapy vs. metformin/sitagliptin (MS) in type 2 diabetes mellitus (T2DM). Methods In this phase 3, multicenter, double-blind study, patients with T2DM who exhibited inadequate glycemic control with HbA1c of 8.0–11.0% while taking ≥1500 mg/day metformin for at least 6 weeks were randomized to receive either FDC of MSP (1000/100/15 mg) or MS (1000/100 mg) per day for 24 weeks. The primary outcome measure was the change in HbA1c, and secondary outcomes included changes in fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and body weight from baseline to 24 weeks along with safety and tolerability. Results Among the 236 patients randomized, 207 (87.71%) successfully completed the study. All baseline characteristics were comparable between the FDC of MSP and MS groups. There was a subsequent significant reduction of HbA1c in FDC of MSP (− 1.64) vs. MS (− 1.32); between groups was [− 0.32% (95% CI, − 0.59, − 0.05)], P = 0.0208. Similar reductions were found in FPG [− 13.2 mg/dL (95% CI, − 22.86, − 3.71)], P = 0.0068, and PPG [− 20.83 mg/dL (95% CI, − 34.11, − 7.55)], P = 0.0023. There were no significant changes in body weight. A total of 27 adverse effects (AEs) and one severe AE were reported, none of which were related to the study drug. Conclusion The FDC of MSP demonstrated significant efficacy in managing glycemic indices and could serve as a valuable tool for physicians in the management of Indian patients with T2DM. Trial registration Clinical Trials Registry of India, CTRI/2021/10/037461.
- Published
- 2024
- Full Text
- View/download PDF
43. Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
- Author
-
Harsh Salankar, Sonali Rode, C Arjun, Rajeeta Joseph, Gourav B Deshmane, and Radhika P Vijayan
- Subjects
diabetes mellitus type 2 ,empagliflozin ,glycated hemoglobin (hba1c) ,metformin therapy ,sitagliptin ,Pharmacy and materia medica ,RS1-441 ,Analytical chemistry ,QD71-142 - Abstract
Introduction: More than 28.7 million individuals throughout the globe suffer from diabetes mellitus, with an estimated 11 percent of the population living with the condition in India. Changes in lifestyle and a variety of treatment plans are used in management. Metformin is a key drug for glycemic control, both when used alone and in combination. Our research compares the effectiveness of glycemic control achieved by empagliflozin plus sitagliptin. Methods: This study took place from November 2022 to April 2023 at the tertiary care hospital. The study did not begin until the ethical review was completed. There were two groups of patients, A and B. Everyone received a daily dose of Metformin 1,000 milligrams. Sitagliptin (50 mg twice daily) was administered to individuals in Group A, whereas Empagliflozin (10 mg once daily) was given to those in Group B. After three months of therapy, HbA1c was used to compare the two groups' levels of glycemic control to those at the start of treatment. To do this, we employed a proforma. Version 25 of the Statistical Package for the Social Sciences (SPSS Inc., Chicago, USA) was used for the analysis. Results: The average age of the 300 patients that participated in the trial was 42.33. There were 57.67% men and 42.33% females. “The mean reduction in HbA1c from baseline in Group A was −0.65 ± 0.11% and in Group B was −1.34 ± 0.13% with statistically significant P-value (P-value = 0.000).” Conclusion: The combination of Empagliflozin and Metformin is superior to that of Sitagliptin and Metformin for the maintenance of glycemic control.
- Published
- 2024
- Full Text
- View/download PDF
44. Commitment to innovation drives Bioaltus Pharmaceuticals
- Subjects
Sitagliptin ,Regulatory compliance ,Patient compliance ,Drug discovery ,Ticagrelor -- Innovations ,Pharmaceutical industry -- International economic relations -- Training ,Pharmaceuticals and cosmetics industries - Abstract
Bioaltus Pharmaceuticals has emerged as a dynamic leader in the pharmaceutical industry, driven by its commitment to innovation, global expansion, and a focus on unmet medical needs. From its humble [...]
- Published
- 2024
45. MDC recommends retail prices for anti-diabetes combinations of empagliflozin
- Subjects
Boehringer Ingelheim GmbH -- Intellectual property ,Sitagliptin ,Dapagliflozin ,Diabetes therapy -- Prices and rates ,Drug therapy, Combination ,Pharmaceutical industry -- Intellectual property ,Company pricing policy ,Pharmaceuticals and cosmetics industries - Abstract
Byline: Gireesh Babu The Multidisciplinary Committee (MDC) of experts with the National Pharmaceutical Pricing Authority (NPPA) has recommended retail price of combinations containing diabetes drug empagliflozin, for which patent for [...]
- Published
- 2024
46. July 2024: Notable Drug Approvals
- Author
-
Duffy, Steve
- Subjects
Psoriasis -- Drug therapy ,Sitagliptin ,Aprepitant ,Children -- Health aspects ,Drug approval ,Interleukins ,Food allergy -- Drug therapy ,Type 2 diabetes -- Drug therapy ,Roflumilast ,Health - Abstract
Drug Pharmacologic Class Indication More Information Allergic Disorders Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) Oral immunotherapy Treatment of pediatric patients aged 1 to 3 years with peanut allergy. (https://www.empr.com/home/news/palforzia-approval-expanded-to-younger-patients-with-peanut-allergy/) Palforzia [...]
- Published
- 2024
47. NPPA fixes retail price of 70 new drug formulations
- Subjects
Sitagliptin ,Dapagliflozin ,Drug approval ,Clopidogrel ,Telmisartan ,Pharmaceuticals and cosmetics industries - Abstract
Byline: Gireesh Babu The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of a total of 70 new drug formulations, including 12 for which the companies launched the products [...]
- Published
- 2024
48. Researchers at Amiens University Hospital Publish New Data on Chronic Kidney Disease (De-indexed estimated glomerular filtration rates for the dosing of oral antidiabetic drugs in patients with chronic kidney disease)
- Subjects
Medical research ,Medicine, Experimental ,Sitagliptin ,Chronic kidney failure -- Care and treatment ,Body mass index ,Physical fitness ,Health - Abstract
2024 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on chronic kidney disease. According to news originating [...]
- Published
- 2024
49. FDA Approves Zituvimet XR for Type 2 Diabetes
- Author
-
Ernst, Diana
- Subjects
Sitagliptin ,Diabetes therapy ,Drug approval ,Type 2 diabetes -- Drug therapy ,Health ,Zituvimet (Medication) - Abstract
The Food and Drug Administration (FDA) has approved Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets as an adjunct to diet and exercise to improve glycemic control in adults with [...]
- Published
- 2024
50. Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax.
- Author
-
Abd-Eldayem, Ahmed M., Makram, Sohayla Mahmoud, Messiha, Basim Anwar Shehata, Abd-Elhafeez, Hanan H., and Abdel-Reheim, Mustafa Ahmed
- Subjects
- *
HESPERIDIN , *NUCLEAR factor E2 related factor , *SITAGLIPTIN , *KIDNEYS , *SERUM albumin - Abstract
Cyclosporine A (CsA) is employed for organ transplantation and autoimmune disorders. Nephrotoxicity is a serious side effect that hampers the therapeutic use of CsA. Hesperidin and sitagliptin were investigated for their antioxidant, anti-inflammatory, and tissue-protective properties. We aimed to investigate and compare the possible nephroprotective effects of hesperidin and sitagliptin. Male Wistar rats were utilized for induction of CsA nephrotoxicity (20 mg/kg/day, intraperitoneally for 7 days). Animals were treated with sitagliptin (10 mg/kg/day, orally for 14 days) or hesperidin (200 mg/kg/day, orally for 14 days). Blood urea, serum creatinine, albumin, cystatin-C (CYS-C), myeloperoxidase (MPO), and glucose were measured. The renal malondialdehyde (MDA), glutathione (GSH), catalase, and SOD were estimated. Renal TNF-α protein expression was evaluated. Histopathological examination and immunostaining study of Bax, Nrf-2, and NF-κB were performed. Sitagliptin or hesperidin attenuated CsA-mediated elevations of blood urea, serum creatinine, CYS-C, glucose, renal MDA, and MPO, and preserved the serum albumin, renal catalase, SOD, and GSH. They reduced the expressions of TNF-α, Bax, NF-κB, and pathological kidney damage. Nrf2 expression in the kidney was raised. Hesperidin or sitagliptin could protect the kidney against CsA through the mitigation of oxidative stress, apoptosis, and inflammation. Sitagliptin proved to be more beneficial than hesperidin. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.